Arrowhead Research | ARWR - Betriebsergebnis

Aktienkurs
72.87
Täglich Wechseln
2.34 3.32%
Monatlich
16.22%
Jährlich
419.02%
Q2 Prognose
72.33




Betriebsergebnis Veränderung Datum
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12
Xencor USD -53.63M 6.11M 2025-12